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Abstracts
Gregory L. Moneta, MD, Section EditorEvaluation of Surveillance Bias and the Validity of the Venous
Thromboembolism Quality Measure
Billimoria KY, Chung J, Ju MH, et al. JAMA 2013;310:1482-9.
Conclusions: The venous thromboembolism (VTE) quality measure
for hospitals is limited by surveillance bias.
Summary: The Agency for Healthcare Research and Quality
(AHRQ) developed a risk-adjusted postoperative VTE measure, Patient
Safety Indicator 12 (http://www.qualityindicators.ahrq.gov/Downloads/
Modules/PSI/V44/TechSpecs/PSI%2012%20Postoperative%20PE%200r
%20DVT%20Rate.pdf). However, hospitals more vigilant in performing im-
aging studies for VTE could possibly identify more VTE events. This could
paradoxically result in worse performance on the AHRQ VTE outcome
measure. Measuring VTE rates may be ﬂawed because of surveillance
bias, a “the more you look, the more you ﬁnd” phenomenon. The authors
sought to examine the effect of surveillance bias on the validity of VTE as a
quality measure. They performed three analyses. National hospital-level data
were used to examine the relationship between VTE prophylaxis adherence
and VTE event rates. Those data were then used to examine associations be-
tween hospital characteristics reﬂecting higher quality in-hospital and VTE
event rates and VTE prophylaxis. Finally, associations between VTE events
in-hospital and VTE in-hospital imaging rates were examined with patient-
level Medicare claims data. The 2010 Hospital Compare and American
Hospital Association data from 2838 hospitals were merged. Medicare
claims data (2009-2010) for 954,926 surgical patient discharges from
2786 hospitals undergoing one of 11 major operations were then used to
calculate VTE imaging rates and VTE event rates. Main outcome measures
included the association between hospital VTE prophylaxis adherence and
risk-adjusted VTE event rates. The relationship between a summary score
of hospital structural characteristics reﬂecting quality and performance on
VTE prophylaxis and risk-adjusted VTE measures was then examined. Hos-
pital-level VTE event rates were compared across VTE diagnostic imaging
rate quartiles with a quantile regression. Data indicated that greater hospital
VTE prophylaxis adherence rates were weakly associated with worse risk-
adjusted VTE event rates (r2 ¼ 4.2%; P ¼ .03). Hospitals with increasing
structural quality scores had higher VTE prophylaxis adherence rates
(93.3% vs 95.5%, lowest vs highest quartile; P < .001) but also had worse
risk-adjusted VTE rates (4.8 vs 6.4 per 1000, lowest vs highest quartile;
P < .001). VTE imaging diagnostic rates ranged from 32 studies per
1000 in the lowest imaging use quartile to 167 per 1000 in the highest im-
aging use quartile (P < .001). Risk-adjusted VTE rates increased with VTE
imaging use rates in a stepwise fashion from 5.0 per 1000 in the lowest quar-
tile to 13.5 per 1000 in the highest quartile (P < .001).
Comment: The data seem to conﬁrm the “more you look the more
you ﬁnd” phenomenon. Higher VTE prophylaxis adherence was not asso-
ciated with lower VTE rates in hospitals with higher characteristics reﬂecting
quality and higher VTE event rates. In addition, hospital risk-adjusted VTE
rates were correlated with VTE imaging use rates. The data bring into ques-
tion the use of AHRQ Patient Safety Indicator 12, postoperative VTE rates,
as an isolated measure of hospital quality and safety.
Meta-Analysis of Contemporary Short- and Long-Term Mortality
Rates in Patients Diagnosed With Critical Leg Ischemia
Rollins KE, Jackson D, Coughlin PA Br J Surg 2013;100:1002-8.
Conclusions: Early mortality rates in patients with critical limb
ischemia (CLI) are improving compared with historic data, but long-term
mortality rates remain high.
Summary: CLI is likely a disease that will increase in prevalence, given
the increase in the incidence of diabetes and an aging population. The au-
thors of this article point out that the natural history of CLI is often
described as “at presentation vascular reconstruction will be attempted in
50-60% of patients, with approximately 25% having a primary amputation;
after one year, 20-25% of patients will have died, with only 25% being alive
without major amputation and free of symptoms from CLI” (Becker F et al,
Eur J Vasc Endovasc Surg 2011;42(Suppl 2):S4-12). This impression of the
natural history of CLI is based primarily on historic data, and the authorssought to examine modern studies reporting mortality rates in patients diag-
nosed with CLI and then combine these results with a meta-analysis. The
authors performed a systematic literature search for studies prospectively
reporting mortality in patients with CLI. Overall mortality rates and speciﬁc
patient-related factors associated with death were analyzed with meta-
analysis and meta-regression models. A total of 50 studies were included
in the analysis. At 30 days, the estimated probability of all-cause mortality
in patients diagnosed with CLI was 3.7%. Mortality was 17.5% at 1 year,
35.1% at 3 years, and 46.2% at 5 years. There was a statistically signiﬁcant
survival beneﬁt for men at 30 days and 3 years. Older age, tissue loss, and
presence of ischemic heart disease were associated with a higher probability
of death at 3 years.
Comment: Mortality for CLI patients is still frighteningly high.
Despite improvements in medical treatment of cardiovascular risk factors
and in management of secondary risk factors, there does not appear to
have been a lot of progress made in improving mortality rates of patients
with CLI. In addition, the authors note some studies provided details of
lost to follow-up, but many did not. Despite this, the authors handled
follow-up data of all studies in the same way regardless of the extent of
or how follow-up was reported. Lost to follow-up (both known and un-
known) was treated as survival; therefore, the mortality rates listed here
should be considered conservative and are likely to be higher than the
quoted value.
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli G, Buller HR, Cohen A, and the AMPLIFY Investigators. N Engl J
Med 2013;369:799-808.
Conclusions: A ﬁxed-dose regimen of apixaban was not inferior to
conventional therapy for treatment of acute venous thromboembolism
(VTE), with less risk of bleeding.
Summary: Apixaban is a factor Xa inhibitor, given orally, with rapid
onset of action and predictable pharmacokinetics. It is given in a ﬁxed-
dose regimen. Apixaban has been shown to prevent recurrent VTE in pa-
tients who completed 6 to 12 months of anticoagulant therapy for acute
VTE. Major bleeding was similar to those with placebo (Agnelli G et al, N
Engl J Med 2013;368:699-708). In this study, apixaban was compared
with conventional anticoagulation in patients with acute symptomatic
VTE. This was a randomized double-blind study comparing apixaban at
a ﬁxed dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily
for 6 months to conventional therapy (subcutaneous enoxaparin, followed
by warfarin) in 5395 patients with acute VTE. Recurrent symptomatic
VTE, or death related to VTE, were the primary efﬁcacy outcomes. Major
bleeding alone and major bleeding plus clinically relevant nonmajor
bleeding were the principle safety outcomes. The primary efﬁcacy
outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group
compared with 71 of 2635 (2.7%) in the conventional-therapy group
(relative risk, 0.84; 95% conﬁdence interval [CI], 0.60-1.18; difference
in risk [apixaban minus conventional therapy], 0.04 percentage points;
95% CI, 1.3 to 0.4). Compared with predeﬁned upper limits of the
95% CI for relative risk (1.80) and difference in risk (<3.5% points)
apixaban was not inferior to conventional therapy. Major bleeding
occurred in 0.6% and 1.8% of the patients receiving the apixaban and con-
ventional therapy, respectively (relative risk, 0.31; 95% CI, 0.17-0.55; P <
.001 for superiority). The composite outcome of major bleeding and clin-
ically relevant nonmajor bleeding occurred in 4.3% of the apixaban group
compared with 9.7% in the conventional therapy group (relative risk, 0.44;
95% CI, 0.36-0.55; P < .001). Other adverse events rates were similar in
the two groups.
Comment: Although additional information is needed concerning
the efﬁcacy of apixaban for treatment of VTE in patients with low body
weight, cancer, or low creatinine clearance levels, the results of this study
combined with the apixaban for the extended treatment of deep venous
thrombosis and pulmonary embolism trial indicate apixaban is effective
and safe for both initial and long-term treatment of VTE. It appears for
the majority of patients with VTE, a new paradigm for treatment of acute
VTE is rapidly approaching.269
